

BIOCON GROUP

FINANCIALS

Q3 FY 2005 vs Q3 FY 2004

9M FY 2005 vs 9M FY 2004

FACT SHEET

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT
(Rs. crores)

Particulars	Q3 FY 2005	Q3 FY 2004	Variance Q3 FY 05 vs Q3 FY 04	Nine Months ended FY 05	Nine Months ended FY 04	Variance FY 05 vs FY 04	Full Year ended March 31, 2004
INCOME							
Biopharmaceuticals	138	113	22%	426	321	33%	436
Enzymes	22	16	35%	65	48	36%	66
Contract research	18	10	93%	47	27	75%	39
Total Sales	178	139	28%	538	396	36%	541
Other income	5	0		12	1		1
Total Income	183	139	31%	550	397	39%	542
EXPENDITURE							
Manufacturing & other exp	118	96	24%	363	266	36%	362
PBIDT	65	43	49%	187	131	43%	180
Interest and finance charges	1	0		2	2		2
PBDT	64	43	48%	185	129	43%	178
Depreciation	6	4		16	12		16
PBT	58	39	47%	169	117	44%	162
Taxes	8	4		15	22		23
PROFIT FOR THE PERIOD	50	35	42%	154	95	62%	139
Minority interest	(0)	(0)		(1)	-		-
NET PROFIT (PAT)	50	35	44%	155	95	63%	139
EPS on issued capital- (Rs)	5.0	3.9	30%	15.5	10.6	46%	13.9

NOTE: The figures are rounded off to nearest crores, percentages are based on absolute numbers

BIOCON LIMITED (CONSOLIDATED)			
BALANCE SHEET			
<i>(Rs. crores)</i>			
Particulars	As on 31-Dec-04	As on 31-Dec-03	As on 31-Mar-04
<u>SOURCES OF FUNDS</u>			
Share Capital	50	45	50
Reserves & Surplus	671	185	513
Total Shareholder's Funds	721	230	563
Minority interest	1	0	0
Deferred Tax Liability	22	16	18
Secured Loans	68	49	47
Unsecured Loans	24	16	17
Total Loan Funds	92	65	64
Total	836	311	645
<u>APPLICATION OF FUNDS</u>			
Fixed Assets, net	481	192	219
Investments	297	14	22
Inventories	86	70	86
Sundry debtors	165	140	119
Cash and bank balances	2	2	317
Loans and advances	15	14	23
Total Current Assets, Loans & Advances	268	226	544
Less: Current liabilities and provisions	210	121	140
Net Current assets	58	105	404
Total	836	311	645

BIOCON LIMITED (CONSOLIDATED)			
STATEMENT OF CASH FLOWS			<i>(Rs. crores)</i>
Particulars	Nine Months FY 2005	Nine Months FY 2004	Full Year ended March 31, 2004
<u>I. Cash Flow from Operating Activities</u>			
Net profit before tax	169	117	162
Less/Add: non-cash items/ items required separately			
Depreciation	16	12	16
Others	(9)	3	2
Changes in working capital and other provisions	(48)	(40)	(32)
Cash generated from operations	128	92	148
Tax paid (net of refunds)	(6)	(15)	(20)
Net Cash provided by operating activities	122	77	128
<u>II. Cash Flow from Investing Activities</u>			
Fixed Assets	(199)	(64)	(93)
Interest / dividend received	10	1	2
Investments	(275)	(9)	(17)
Net cash used for investing activities	(464)	(72)	(108)
<u>III. Cash Flows from Financing Activities</u>			
Proceeds from issuance of share capital (net of expenses)	0	0	300
Borrowings and other financing activities	27	(6)	(6)
Net Cash provided/(used) for financing activities	27	(6)	294
<u>IV. Net Change in Cash and Cash Equivalents (I+II+III)</u>	(315)	(1)	314
<u>V. Cash & Cash Eq. at the beginning of the year</u>	317	3	3
<u>VI CASH AND CASH EQUIVALENTS OF THE ESOP TRUST</u>	0	0	0
<u>ACQUIRED DURING THE YEAR</u>			
<u>VI. Cash and Cash Eq. at the end of the year (IV+V)</u>	2	2	317

BIOCON LIMITED (STANDALONE)							
PROFIT & LOSS STATEMENT							(Rs. crores)
Particulars	Q3 FY 2005	Q3 FY 2004	Variance Q3 FY 05 vs Q3 FY 04	Nine Months FY 05	Nine Months FY 04	Variance FY 05 vs FY 04	Full Year ended March 31, 2004
INCOME							
Sales	160	129	24%	491	369	33%	502
Contract research fees	0	0		0	1		1
Total Sales	160	129	0	491	370	0	503
Other income	5	0		12	1		1
Total	165	129	27%	503	371	36%	503
EXPENDITURE							
Manufacturing & other exp	108	90	20%	337	251	34%	341
PBIDT	56	39	43%	166	120	38%	163
Interest and finance charges	1	0		2	1		2
PBDT	56	39	42%	164	119	38%	161
Depreciation	5	4		13	10		14
PBT	51	35	42%	151	109	39%	148
Taxes	5	4		12	22		23
NET PROFIT (PAT)	46	31	45%	139	87	61%	125
EPS – (Rs)	4.6	3.5	32%	13.9	9.6	45%	12.5
NOTE: The figures are rounded off to nearest crores, percentages are on absolute numbers							

SYNGENE INTERNATIONAL PRIVATE LIMITED (STANDALONE)							
PROFIT & LOSS STATEMENT							(Rs. crores)
Particulars	Q3 FY 2005	Q3 FY 2004	Variance Q3 FY 05 vs Q3 FY 04	Nine Months FY 05	Nine Months FY 04	Variance FY 05 vs FY 04	Full Year ended March 31, 2004
INCOME							
Contract research fees	15	8	100%	40	21	88%	32
Sale of compounds	2	1	316%	7	5	45%	6
Other income	0	0		1	0		0
Total	18	9	106%	47	26	80%	38
EXPENDITURE							
Contract research & other exp	9	5	83%	23	14	62%	20
PBDIT	9	4	136%	24	13	99%	18
Interest and finance charges	0	0		0	0		0
PBDT	9	4	137%	24	13	100%	18
Depreciation	1	0		2	2		2
PBT	7	4	103%	22	11	107%	16
Taxes	3	-		3	0		0
NET PROFIT (PAT)	4	4	21%	19	11	81%	16
NOTE: The figures are rounded off to nearest crores, percentages are on absolute numbers							

CLINIGENE INTERNATIONAL PRIVATE LIMITED (STANDALONE)							
PROFIT & LOSS STATEMENT							(Rs. crores)
Particulars	Q3 FY 2005	Q3 FY 2004	Variance Q3 FY 05 vs Q3 FY 04	Nine Months ended FY 05	Nine Months ended FY 04	Variance FY 05 vs FY 04	Full Year ended March 31, 2004
INCOME							
Contract research fees	1	0		1	0		1
Other income	0	0		0	0		0
Total	1	0		1	0		1
EXPENDITURE							
Contract research & other exp	1	1	34%	3	2	42%	3
PBDIT	(0)	(1)	-68%	(2)	(2)	0%	(2)
Interest and finance charges	0	0		0	0		0
PBDT	(0)	(1)	-67%	(2)	(2)	2%	(2)
Depreciation	0	0		0	0		0
PBT	(0)	(1)	-45%	(2)	(2)	21%	(2)
Taxes	0	0		0	0		0
NET PROFIT /(LOSS)	(0)	(1)	-45%	(2)	(2)	21%	(2)
NOTE: The figures are rounded off to nearest crores, percentages are on absolute numbers							